Eupraxia Pharmaceuticals Inc.
EPRXHealthcare|Biotechnology|CA
$6.89
+0.29 (+4.39%)
DCF Value
$1.44
Tangible Book / Share
$1.95
Cash / Share
$2.02
Financials
Financial Snapshot
Market Cap
$455.2M
Enterprise Value
$404.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$50.2M
Cash & Investments
$133.4M
Net Cash
$131.6M
Free Cash Flow (TTM)
-$36.6M
Operating CF (TTM)
-$35.9M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$133.4M
Quarterly Burn
$9.0M
Monthly Burn
$3.0M
Est. Runway
~14.9 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.0M | $823.5K | $1.2M | $150.1K | $29.9M | $24.7M | $14.6M | $33.1M | $80.6M | $133.4M | |
| Operating Cash Flow | -$5.3M | -$8.3M | -$5.2M | -$403.8K | -$11.6M | -$14.4M | -$15.6M | -$30.0M | -$29.0M | -$35.9M | |
| Free Cash Flow | -$5.6M | -$8.5M | -$5.2M | -$403.8K | -$11.9M | -$14.6M | -$15.7M | -$30.1M | -$29.6M | -$36.6M | |
| Capital Expenditure | -$314.7K | -$141.9K | -$9.5K | $0.00 | -$341.3K | -$235.6K | -$55.2K | -$104.2K | -$598.8K | -$731.4K | |
| Financing Cash Flow | $9.5M | $5.3M | $7.4M | -$626.6K | $39.5M | $10.8M | $15.9M | $45.8M | $77.3M | $129.6M |
R&D Spending
R&D (TTM)
$36.3M
R&D Intensity
—
R&D Growth vs Prior
+70.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $3.4M | $6.8M | $3.5M | $1.1M | $10.2M | $13.6M | $15.3M | $16.1M | $21.3M | $36.3M | |
| SG&A | $1.5M | $5.1M | $3.1M | $1.3M | $8.2M | $4.0M | $5.6M | $10.9M | $17.1M | $20.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $86.6K | $125.4K | $207.4K | $117.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$86.6K | -$125.4K | -$207.4K | -$117.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $3.4M | $6.8M | $3.5M | $1.1M | $10.2M | $13.6M | $15.3M | $16.1M | $21.3M | $36.3M | |
| SG&A | $1.5M | $5.1M | $3.1M | $1.3M | $8.2M | $4.0M | $5.6M | $10.9M | $17.1M | $20.8M | |
| Operating Income | -$4.9M | -$12.0M | -$6.8M | -$2.5M | -$18.4M | -$17.6M | -$21.0M | -$27.0M | -$38.4M | -$57.1M | |
| Interest Expense | $52.8K | $142.2K | $1.5M | $1.9M | $1.2M | $982.9K | $881.1K | $603.6K | $0.00 | $0.00 | |
| Pretax Income | -$5.1M | -$14.8M | -$7.4M | -$4.0M | -$24.3M | -$19.0M | -$21.8M | -$25.7M | -$38.6M | -$50.2M | |
| Net Income | -$4.4M | -$13.2M | -$7.4M | -$4.0M | -$24.0M | -$18.5M | -$21.2M | -$25.5M | -$38.6M | -$50.2M | |
| EPS (Diluted) | -0.34 | -1.03 | -0.56 | -0.31 | -1.93 | -0.96 | -0.88 | -0.76 | -1.03 | -0.99 | |
| EBITDA | -$4.9M | -$14.5M | -$5.7M | -$2.0M | -$17.8M | -$17.9M | -$20.8M | -$25.0M | -$38.3M | -$49.8M | |
| Shares Out. (M) | 12.87 | 12.87 | 12.87 | 12.87 | 12.41 | 19.29 | 24.15 | 33.93 | 39.96 | 66.22 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.0M | $823.5K | $1.2M | $150.1K | $20.9M | $24.7M | $14.6M | $33.1M | $80.6M | $52.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $9.0M | $0.00 | $0.00 | $0.00 | $0.00 | $81.1M | |
| Total Current Assets | $5.5M | $2.5M | $2.6M | $1.1M | $30.6M | $25.2M | $14.9M | $34.4M | $85.1M | $136.5M | |
| Total Assets | $5.9M | $2.9M | $3.3M | $1.5M | $31.2M | $25.9M | $15.3M | $34.9M | $86.2M | $139.6M | |
| Total Current Liabilities | $730.7K | $14.3M | $20.7M | $22.5M | $2.3M | $4.1M | $14.6M | $3.1M | $5.6M | $8.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $9.7M | $11.9M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $735.8K | $14.3M | $21.4M | $23.1M | $12.1M | $16.1M | $14.6M | $3.1M | $5.7M | $10.2M | |
| Stockholders' Equity | $6.0M | -$11.1M | -$17.7M | -$21.2M | $20.0M | $10.5M | $1.7M | $33.4M | $82.0M | $131.0M | |
| Retained Earnings | -$20.1M | -$40.0M | -$47.2M | -$51.2M | -$74.3M | -$104.6M | -$79.4M | -$131.0M | -$169.6M | -$196.3M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.3M | -$8.3M | -$5.2M | -$403.8K | -$11.6M | -$14.4M | -$15.6M | -$30.0M | -$29.0M | -$35.9M | |
| Capital Expenditure | -$314.7K | -$141.9K | -$9.5K | $0.00 | -$341.3K | -$235.6K | -$55.2K | -$104.2K | -$598.8K | -$731.4K | |
| Free Cash Flow | -$5.6M | -$8.5M | -$5.2M | -$403.8K | -$11.9M | -$14.6M | -$15.7M | -$30.1M | -$29.6M | -$36.6M | |
| Investing Cash Flow | -$314.7K | -$141.9K | -$1.9M | $24.6K | -$11.4M | $9.8M | -$55.2K | -$75.2K | -$598.8K | -$79.7M | |
| Financing Cash Flow | $9.5M | $5.3M | $7.4M | -$626.6K | $39.5M | $10.8M | $15.9M | $45.8M | $77.3M | $129.6M | |
| Issuance of Stock | $7.2M | $1.7M | $0.00 | $0.00 | $29.9M | $10.6M | $12.0M | $54.6M | $77.3M | $129.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $463.1K | $2.7M | $4.4M | -$1.1M | $9.6M | -$142.3K | -$59.8K | -$9.1M | $0.00 | $0.00 | |
| Stock Based Comp. | $162.8K | $2.9M | $545.0K | $228.7K | $0.00 | $1.4M | $1.1M | $3.2M | $0.00 | $319.8K | |
| Net Change in Cash | $3.9M | -$3.2M | $332.6K | -$1.0M | $16.4M | $5.7M | $811.9K | $13.8M | $47.3M | $13.1M |
Dilution Tracker
Shares outstanding grew 210.6% over 5 years — significant dilution
Shares Outstanding
66M
5-Year Share Growth
+210.6%
Stock Issuance (TTM)
$129.6M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.87 | 12.87 | 12.87 | 12.87 | 12.41 | 19.29 | 24.15 | 33.93 | 39.96 | 66.22 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | -3.6% | 55.5% | 25.2% | 40.5% | 17.8% | 65.7% | |
| Stock Issuance | $7.2M | $1.7M | $0.00 | $0.00 | $29.9M | $10.6M | $12.0M | $54.6M | $77.3M | $129.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $162.8K | $2.9M | $545.0K | $228.7K | $0.00 | $1.4M | $1.1M | $3.2M | $0.00 | $319.8K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -73.3% | 119.3% | 41.7% | 18.9% | -120.1% | -175.4% | -1273.4% | -76.3% | -47.0% | -45.3% | |
| ROA % | -73.9% | -453.4% | -224.4% | -275.6% | -76.7% | -71.4% | -139.3% | -73.0% | -44.8% | -35.7% | |
| ROIC % | -94.6% | 157.4% | 119.8% | 29.0% | -63.1% | -80.4% | -245.5% | -84.6% | -47.7% | -43.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -44.8% | -65.4% | 43.6% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -144.1% | 43.2% | 63.7% | -642.6% | 4.1% | -19.0% | -28.8% | -42.3% | |
| Net Income | 0.0% | -201.1% | 44.1% | 45.7% | -498.0% | 22.8% | -14.9% | -20.0% | -51.3% | |
| EPS (Diluted) | 0.0% | -202.9% | 45.6% | 44.6% | -522.6% | 50.3% | 8.3% | 13.6% | -35.5% | |
| Operating Cash Flow | 0.0% | -57.0% | 37.9% | 92.2% | -2766.8% | -24.4% | -8.5% | -92.0% | 3.2% | |
| Free Cash Flow | 0.0% | -50.8% | 38.8% | 92.2% | -2851.3% | -22.8% | -7.2% | -92.0% | 1.6% | |
| R&D Expense | 0.0% | 102.6% | -48.3% | -69.2% | 837.5% | 34.0% | 12.5% | 4.9% | 32.7% | |
| SG&A Expense | 0.0% | 243.9% | -39.2% | -58.9% | 544.7% | -51.4% | 41.3% | 93.9% | 56.6% | |
| Total Assets | 0.0% | -50.9% | 12.9% | -55.8% | 2047.9% | -17.1% | -41.1% | 129.0% | 146.5% | |
| Book Value / Share | 0.0% | -320.3% | -58.6% | -19.5% | 191.5% | -67.2% | -94.5% | 3272.5% | 114.6% | |
| Debt | 0.0% | 30307.0% | 214.7% | 7.0% | -21.8% | 21.8% | -35.3% | -99.1% | 114.8% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | -3.6% | 55.5% | 25.2% | 40.5% | 17.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B3.48
10Y Low / Med / High2.32 / 7.31 / 42.69
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.44
Tangible Book / Share
$1.95
Net Current Assets / Share
$1.91
Graham Net-Net
$1.87
Cash / Share
$2.02
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -10.92 | -3.91 | -6.84 | -12.14 | -1.93 | -4.16 | -3.35 | -4.17 | -7.33 | -6.74 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 7.99 | -4.68 | -2.78 | -2.28 | 2.32 | 7.31 | 42.69 | 3.22 | 3.68 | 3.48 | |
| EV/EBITDA | -8.87 | -3.77 | -10.47 | -30.26 | -1.98 | -3.61 | -3.11 | -2.99 | -5.77 | -7.25 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
35.72
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $708.1K | $1.8M |
| Net Income | -$44.0M | -$44.6M | -$64.3M |
| EPS | $-1.26 | $-1.41 | $-1.65 |
| # Analysts (EPS) | 7 | 8 | 7 |